BACKGROUND AND OBJECTIVES: Fabry disease is a progressive X-linked disorder of glycosphingolipid metabolism that typically presents in childhood and progresses to heart failure and renal failure in adulthood. This study sought to determine the prevalence of Fabry disease in a multiethnic male chronic kidney disease population, involving dialysis-dependent, non-dialysis-dependent, and transplant patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 499 patients were screened with assay of alpha-galactosidase activity using fluorometric enzyme assay on plasma prepared from fresh heparinized blood, followed by leukocyte alpha-galactosidase activity in the subset of patients with plasma alpha-galactosidase activity below the second percentile (corresponding to a value <3.0 nmol/h per ml plasma). RESULTS: This study did not identify any new cases of Fabry disease; however, repeat testing of some of the study patients identified three limitations of the plasma enzyme assay that is commonly used as a high throughput screening method for Fabry disease: (1) False-negative results can occur; (2) these false-negative results are not prevented by use of inhibitors of alpha-galactosidase B activity; and (3) considerable intraindividual variation in plasma alpha-galactosidase levels reduces the discriminatory power of the screening test. CONCLUSION: Clinicians need to be aware that screening using plasma will fail to detect some patients with Fabry disease.
BACKGROUND AND OBJECTIVES:Fabry disease is a progressive X-linked disorder of glycosphingolipid metabolism that typically presents in childhood and progresses to heart failure and renal failure in adulthood. This study sought to determine the prevalence of Fabry disease in a multiethnic male chronic kidney disease population, involving dialysis-dependent, non-dialysis-dependent, and transplant patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 499 patients were screened with assay of alpha-galactosidase activity using fluorometric enzyme assay on plasma prepared from fresh heparinized blood, followed by leukocyte alpha-galactosidase activity in the subset of patients with plasma alpha-galactosidase activity below the second percentile (corresponding to a value <3.0 nmol/h per ml plasma). RESULTS: This study did not identify any new cases of Fabry disease; however, repeat testing of some of the study patients identified three limitations of the plasma enzyme assay that is commonly used as a high throughput screening method for Fabry disease: (1) False-negative results can occur; (2) these false-negative results are not prevented by use of inhibitors of alpha-galactosidase B activity; and (3) considerable intraindividual variation in plasma alpha-galactosidase levels reduces the discriminatory power of the screening test. CONCLUSION: Clinicians need to be aware that screening using plasma will fail to detect some patients with Fabry disease.
Authors: Y Nagao; H Nakashima; Y Fukuhara; M Shimmoto; A Oshima; Y Ikari; Y Mori; H Sakuraba; Y Suzuki Journal: Clin Genet Date: 1991-03 Impact factor: 4.438
Authors: W von Scheidt; C M Eng; T F Fitzmaurice; E Erdmann; G Hübner; E G Olsen; H Christomanou; R Kandolf; D F Bishop; R J Desnick Journal: N Engl J Med Date: 1991-02-07 Impact factor: 91.245
Authors: Soumeya Bekri; Adrian Enica; Thomas Ghafari; Gisèle Plaza; Isabelle Champenois; Gabriel Choukroun; Robert Unwin; Philippe Jaeger Journal: Nephron Clin Pract Date: 2005-05-09
Authors: S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba Journal: N Engl J Med Date: 1995-08-03 Impact factor: 91.245
Authors: Markus Kosch; Hans-Georg Koch; Joao Paulo Oliveira; Carlos Soares; Francesco Bianco; Frank Breuning; Ase Krogh Rasmussen; Roland M Schaefer Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Andreas D Kistler; Justyna Siwy; Frank Breunig; Praveen Jeevaratnam; Alexander Scherl; William Mullen; David G Warnock; Christoph Wanner; Derralynn A Hughes; Harald Mischak; Rudolf P Wüthrich; Andreas L Serra Journal: PLoS One Date: 2011-06-15 Impact factor: 3.240
Authors: Daniel Oder; Nurcan Üçeyler; Dan Liu; Kai Hu; Bernhard Petritsch; Claudia Sommer; Georg Ertl; Christoph Wanner; Peter Nordbeck Journal: BMJ Open Date: 2016-04-08 Impact factor: 2.692
Authors: Mustafa A Kamani; Philippe Provençal; Michel Boutin; Natalia Pacienza; Xin Fan; Anton Novak; Tonny C Huang; Beth Binnington; Bryan C Au; Christiane Auray-Blais; Clifford A Lingwood; Jeffrey A Medin Journal: Future Sci OA Date: 2016-10-13